Effect of targeted versus fixed dosing of nafamostat mesylate on filter life in patients undergoing continuous renal replacement therapy
- 1Department of Internal Medicine, Pusan National University School of Medicine
- 2CKRT Specialized Team, Pusan National University Hospital
Abstract
Nafamostat mesylate (NM) is a commonly used anticoagulant in continuous kidney replacement therapy (CKRT) in Japan and South Korea. NM has been empirically infused at fixed doses (10–20 mg/h) without monitoring. In this single-center before-and-after study, we designed post-filter activated partial thromboplastin time (aPTT)-based targeted NM dosing protocol for CKRT and evaluated its efficacy and safety. The targeted NM dosing protocol involved titrating the NM dose (2.5–5 mg/h) to maintain the post-filter aPTT between 46 and 70 s. Efficacy was assessed by comparing filter lifespan before and after protocol implementation. Safety was evaluated based on changes in the incidence of bleeding complications, leukopenia, and hyperkalemia. Linear mixed-effects and Cox proportional hazards models were used, as appropriate. In total, 151 (before; 91, after; 60) patients received NM-CKRT anticoagulation (68.9% men, mean ages; 68.2 ± 14.2 years). Patient demographics and disease severity were similar before and after protocol implementation. During the intervention, 74.3% of filters reached the target aPTT levels. Compared with fixed dosing, post-filter aPTT-based targeted NM dosing extended the filter life by 4.5 (95% confidence interval; 1.5–7.5) h among filters that achieved the target aPTT levels, without compromising safety issues. Further validation across diverse centers is required.
Related
- Comparison between regional citrate anticoagulation and systemic heparin anticoagulation in patients undergoing continuous renal replacement therapy and venoarterial extracorporeal membrane oxygenation: A retrospective multicentric study
- Chart-Recorded Hourly Patient Fluid-Removal Intensity and 90-Day Mortality After a 12-Hour Landmark During Continuous Renal Replacement Therapy
- Cytokine and Vasopressor Trajectories During Continuous Renal Replacement Therapy with oXiris, CytoSorb, or Standard Haemofilters in Sepsis-Associated Acute Kidney Injury: An Exploratory Retrospective Cohort Study
- Correlation between circulating tumor cell levels and tumor response in patients with advanced hepatocellular carcinoma undergoing immunotherapy and molecular targeted therapy
- Outcomes of rescue procedures in patients undergoing unsuccessful deployment of transcatheter mitral valve replacement.
BibTeX
@article{rhee2026effect,
title = {{Effect of targeted versus fixed dosing of nafamostat mesylate on filter life in patients undergoing continuous renal replacement therapy}},
author = {Harin Rhee and Kyung Sook Jung and Eun Young Ku},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-63297-2},
url = {https://doi.org/10.1038/s41598-026-63297-2},
note = {CC BY},
}
RIS
TY - JOUR
TI - Effect of targeted versus fixed dosing of nafamostat mesylate on filter life in patients undergoing continuous renal replacement therapy
AU - Harin Rhee
AU - Kyung Sook Jung
AU - Eun Young Ku
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-63297-2
UR - https://doi.org/10.1038/s41598-026-63297-2
AB - Nafamostat mesylate (NM) is a commonly used anticoagulant in continuous kidney replacement therapy (CKRT) in Japan and South Korea. NM has been empirically infused at fixed doses (10–20 mg/h) without monitoring. In this single-center before-and-after study, we designed post-filter activated partial thromboplastin time (aPTT)-based targeted NM dosing protocol for CKRT and evaluated its efficacy and safety. The targeted NM dosing protocol involved titrating the NM dose (2.5–5 mg/h) to maintain the post-filter aPTT between 46 and 70 s. Efficacy was assessed by comparing filter lifespan before and after protocol implementation. Safety was evaluated based on changes in the incidence of bleeding complications, leukopenia, and hyperkalemia. Linear mixed-effects and Cox proportional hazards models were used, as appropriate. In total, 151 (before; 91, after; 60) patients received NM-CKRT anticoagulation (68.9% men, mean ages; 68.2 ± 14.2 years). Patient demographics and disease severity were similar before and after protocol implementation. During the intervention, 74.3% of filters reached the target aPTT levels. Compared with fixed dosing, post-filter aPTT-based targeted NM dosing extended the filter life by 4.5 (95% confidence interval; 1.5–7.5) h among filters that achieved the target aPTT levels, without compromising safety issues. Further validation across diverse centers is required.
SN - 2045-2322
ER -